智通财经APP获悉，光大证券发布研报称，考虑到公司在AI医疗创新领域取得多项进展，维持医渡科技 (02158)"买入"评级，近期公司在AI医疗创新领域取得多项进展，包括深度参与北京市医疗领域国家人 工智能应用中试基地、中标III期临床研究项目、新增河北和广州两地"惠民保"业务。 风险提示 深度参与中试基地建设，以核心技术共筑AI医疗创新高地 医疗数字化推进不及预期、医疗数字化行业竞争加剧、生命科学解决方案及健康管理平台和解决方案分 部商业化推进不及预期。 9月12日，公司作为北京市医疗领域国家人工智能应用中试基地的核心生态伙伴，深度参与平台建设与 场景创新，推动多项标杆项目落地：开发区域级受试者招募AI智能体，全面提升受试者招募效率与精 准度，解决临床研究受试者招募难、招募慢的核心痛点，已在6个项目中落地验证;开发北京市AI应用插 件程序，以统一入口方式整合集成多AI应用，大幅减轻医疗机构用户操作和系统集成负担。2025年8 月，国务院发布《关于深入实施"人工智能+"行动的意见》，文件指出，要优化应用发展环境，布局建 设一批国家人工智能应用中试基地。而后，上海、北京、广州、浙江相继宣布启动医疗领域国家人工智 ...

点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 事件： 近期公司在AI医疗创新领域取得多项进展，包括深度参与北京市医疗领域国家人工智能应用中试基地、中标 III期临床研究项目、新增河北和广州两地"惠民保"业务。 深度参与中试基地建设，以核心技术共筑AI医疗创新高地 9月12日，公司作为北京市医疗领域国家人工智能应用中试基地的核心生态伙伴，深度参与平台建设与场景创 新，推动多项标杆项目落地：开发区域级受试者招募AI智能体，全面提升受试者招募效率与精准度，解决临 床研究受试者招募难、招募慢的核心痛点，已在6个项目中落地验证；开发北京市AI应用插件程序，以统一入 口方式整合集成多AI应用，大幅减轻医疗机构用户操作和系统集成负担。2025年8月，国务院发布《关于深入 实施"人工智能 ...

Core Insights - The rapid development of artificial intelligence technology, particularly large models, is significantly transforming the healthcare industry, enhancing service models and technological pathways [2] - The Chinese government emphasizes the integration of AI and healthcare, with policies promoting deep applications of AI in the medical field, aiming to improve diagnostic efficiency and optimize resource allocation [2] - The systematic review of the medical large model industry ecosystem and the exploration of typical application scenarios and business models are crucial for transitioning the industry from "technical exploration" to "scaled implementation" [2] Research Objectives - The iResearch Institute plans to release the "China Medical Large Model Industry Research Report" in 2026, aiming to provide insights into industry development, technological evolution, and market trends [3] - The report will serve as a decision-making reference for medical institutions, technology companies, investment institutions, and policymakers, promoting healthy and orderly industry development [3] Research Content - Define the concept, classification, and development history of medical large models, highlighting their strategic value in the intelligent transformation of healthcare [5] - Analyze the industry chain structure of medical large models and examine their application modes in areas such as medical imaging, clinical assistance, drug development, health management, and traditional Chinese medicine [5] - Assess the commercialization pathways and future development directions of medical large models, providing forward-looking strategic references for industry stakeholders [5] Participation Value - Companies participating in the report will have the opportunity to be included in the iResearch "2026 China Medical Large Model Industry Research Report" industry map and case studies, enhancing brand influence and industry recognition [7] - The report will be published on iResearch's official website and WeChat account, with dissemination through various media channels linked to iResearch [7] - Participants will be invited to attend iResearch's online and offline events in the healthcare and digital intelligence sectors, facilitating in-depth exchanges with industry experts and investment institutions [8] Target Companies - Both listed and unlisted companies engaged in the research, application, or service of medical large models are eligible, including those in medical imaging, clinical assistance, hospital management, drug development, health management, and traditional Chinese medicine [10] - Companies should have at least two years of experience in the relevant field and possess multiple practical case studies demonstrating industry representation and exemplarity [10]

今年年初，商汤医疗已获得美的系盈峰控股、人民卫生出版社集团旗下人卫科技发展公司等机构的上亿 元投资。 据了解，本轮融资将用于医疗大模型的持续迭代、核心产品矩阵的拓展升级以及重点区域市场的布局深 化。 来源：猎云网 近日，智能医疗解决方案提供商商汤医疗完成数亿元新一轮战略融资，本轮投资方包括联想创投、联创 资本、九弦资本、申冉投资等。 多模态医学图像基础模型群，涵盖医学图像、文本、生物信息等数据模态；可针对放射、病理等不同图 像模态，实现检测、分割、分类等任务，并支持小样本、弱标注的高效率模型训练，以突破医疗"长尾 问题"数据样本少、标注难度高的瓶颈。 商汤医疗CEO张少霆表示，未来将持续引入具备生态协同能力的产业合作方、财务投资人，共同构建 AI医疗生态，加速医疗行业智慧化升级。 据悉，商汤医疗构建了医疗健康大语言模型"大医"、多模态医学图像基础模型群，以"通专融合"为技术 路径，推动"未来智慧医院"建设。 "大医"模型，以千亿参数规模的商汤日日新"商量"大语言模型为基模，利用海量高质量医学知识数据训 练而成，具备感知、推理及规划能力。该模型目前可覆盖智能自诊、用药咨询、影像报告结构化、临床 辅助决策等多个细 ...

一系列融资进展，为商汤医疗蓄力加码，资金将用于医疗大模型的持续迭代、核心产品矩阵的拓展升级以及重点区域市场的布局深化。 为庆贺本轮融资圆满礼成及A轮融资正式开启，商汤医疗将于11月28日举办"智启新生，医领未来——商汤医疗新征程启航盛典"。本次盛典采用定向邀请 制，将通过战略合作签约、未来蓝图发布、高管团队集体亮相等重要环节，全面展现商汤医疗新阶段的战略布局与发展愿景。 近日，商汤医疗完成数亿元新一轮战略融资，本轮投资方包括联想创投、联创资本、九弦资本、申冉投资等多家知名投资机构。这一融资进展印证了市场 对商汤医疗领先技术实力、成熟商业模式及价值增长潜力的高度认可。 今年年初，商汤医疗已获得美的系盈峰控股、人民卫生出版社集团旗下人卫科技发展公司等机构的上亿元投资。产业方的联合赋能，正推动商汤医疗AI 技术在真实医疗场景中加速融合迭代，成功搭建起从技术研发到产业落地的关键桥梁。目前，商汤医疗已同步启动A轮融资，融资规模与市场影响力稳步 攀升。 ...

Core Insights - The integration of AI in healthcare is significantly enhancing the quality and accessibility of medical services, particularly in pediatrics and chronic disease management [6][7][13]. AI in Pediatric Healthcare - AI technologies are being utilized to provide advanced screening and diagnostic tools for children, such as AI-powered retinal cameras for eye health assessments and interactive robots for early autism screening [7][8]. - The introduction of AI pediatricians aims to assist healthcare professionals by providing rapid access to the latest research and aiding in the diagnosis of rare diseases [8]. AI in Chronic Disease Management - AI is emerging as a crucial tool in managing chronic diseases, shifting the focus from traditional treatment methods to a more health-centered approach [13][14]. - Continuous Glucose Monitoring (CGM) systems are being developed to provide real-time data for diabetes management, enhancing patient care through personalized recommendations and timely alerts for abnormal blood sugar levels [14][15]. AI in Traditional Chinese Medicine - The application of AI in Traditional Chinese Medicine (TCM) is being explored, with projects aimed at integrating AI for diagnostics and treatment, enhancing the effectiveness and accessibility of TCM practices [10][12]. - The Chinese government is promoting the integration of digital technologies, including AI, into TCM to modernize and improve healthcare delivery [12]. AI in Mental Health - AI is being deployed in mental health services, with systems capable of assessing users' emotional and cognitive states, providing recommendations, and facilitating communication between students and mental health resources [9].

Core Insights - The company has successfully won a bid for multiple AI capability platform projects with Beijing Friendship Hospital, marking significant progress in the smart healthcare sector [1][2] - The project utilizes the company's self-developed medical large model and core technologies for multi-modal data recognition and governance, establishing an intelligent service platform for the hospital [1] - The implementation of this platform has led to substantial improvements in data value extraction and diagnostic efficiency, with specific examples including an 80% increase in medical record entry efficiency and a 15% reduction in consultation time [1] Industry Developments - This initiative aligns with national policies promoting AI empowerment in healthcare, transitioning smart healthcare from single-scenario intelligence to comprehensive digital solutions across the entire diagnosis and treatment process [2] - The company has reinforced its leading position in the healthcare intelligence competition, leveraging its advanced medical capabilities demonstrated in authoritative evaluations like MedBench and its experience with over 30% of top-tier hospitals nationwide [2]

Core Insights - The company, Yunzhisheng (09678), has successfully won a bid for multiple AI capability platform projects with Beijing Friendship Hospital, marking a significant advancement in its smart healthcare technology and commercial application [1] Group 1: Project Details - The project utilizes the company's self-developed medical large model, multimodal data recognition and governance, and text reasoning technologies to create an intelligent service platform that hospitals can operate independently [1] - The platform integrates the hospital's knowledge base to form a specialized medical large model, breaking through traditional medical information construction models [1] Group 2: Operational Efficiency - The company has achieved unified management of multiple models and intelligent integration with business systems, significantly enhancing data value extraction and diagnostic efficiency in various scenarios such as wound image recognition, infection risk assessment, intelligent medical record generation, and follow-up management [1] - For instance, the outpatient medical record generation system at Beijing Friendship Hospital improved record entry efficiency by 80% and reduced consultation time by 15%, leading to a substantial increase in patient satisfaction [1] Group 3: Strategic Alignment - This project aligns with national policies promoting AI empowerment in healthcare, facilitating the transition from single-scenario intelligence to comprehensive digital solutions across the entire diagnostic and treatment process [1] - The company consolidates its leading position in healthcare intelligence competition, leveraging its advanced medical capabilities demonstrated in authoritative evaluations like MedBench and its experience covering over 30% of top-tier hospitals nationwide [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 最新業務進展 本公告乃由雲知聲智能科技股份有限公司（「本公司」）自願作出，旨在知會本公司股東 及潛在投資者有關本公司的最新業務發展情況。 UNISOUND AI TECHNOLOGY CO., LTD. 雲知聲智能科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9678） 自願性公告 於本公告日期，本公司董事會包括：(i)執行董事梁家恩博士、黃偉博士、康恒博士、李霄寒先生、劉升平先生及 李鵬先生；(ii)非執行董事鄺子平先生、李志超先生、汪存富先生及李昂先生；及(iii)獨立非執行董事胡建軍先生、 樊健先生、金慧華女士、張坤博士及陳華先生。 本公司董事會（「董事會」）欣然宣佈，本公司成功中標首都醫科大學北京友誼醫院（「北 京友誼醫院」）AI能力平台等多個智能體（Agent）項目，實現與北京友誼醫院在目前合作 基礎上服務關係的進一步深化，也標誌著本公司在智慧醫療領域的技術落地和商業 ...

Core Insights - The application of medical large models spans clinical, management, education, and public health, promising innovation and advancement in healthcare [2][9] - The market size for China's artificial intelligence large models is projected to reach 431.6 billion yuan by 2025, with the medical large model segment expected to grow to 65.3 billion yuan [2][9] - By 2031, the market size for artificial intelligence large models in China is anticipated to grow to 1487.9 billion yuan, with medical large models reaching 213.4 billion yuan [2][9] Industry Overview - Medical large models are specialized AI models trained for the healthcare sector, primarily based on Transformer architecture, designed to understand and generate medical language and knowledge [3] - These models show significant potential in various medical scenarios, including disease diagnosis, medical imaging, electronic health record analysis, and drug development, enhancing diagnostic accuracy and efficiency [3] Market Size and Growth - The market size for medical large models in China is estimated at 41.8 billion yuan in 2024, with a forecasted increase to 65.3 billion yuan in 2025 and 213.4 billion yuan by 2031 [9][11] - The overall market for artificial intelligence large models in China is projected to grow from 268.9 billion yuan in 2024 to 431.6 billion yuan in 2025, and reach 1487.9 billion yuan by 2031 [7][9] Model Type Distribution - The distribution of medical large models includes 114 general medical models (40.57%), 106 specialized medical models (37.72%), and 33 traditional Chinese medicine models (11.74%) [11] Competitive Landscape - Key listed companies in the medical large model sector include Alibaba-W, iFlytek Medical Technology, Yidu Tech, Weining Health, and Zhiyun Health [2] - Relevant institutions and companies involved in the sector include Ruijin Hospital, West China Hospital, Fudan University Zhongshan Hospital, Zhejiang University, Shanghai Jiao Tong University, Baidu, Huawei, and Deepwise Medical [2]